IDEXX LABORATORIES INC (IDXX) Fundamental Analysis & Valuation
NASDAQ:IDXX • US45168D1046
608.41 USD
-10.51 (-1.7%)
At close: Mar 6, 2026
608.41 USD
0 (0%)
After Hours: 3/6/2026, 8:26:14 PM
This IDXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX has a correct valuation and a medium growth rate. With these ratings, IDXX could be worth investigating further for quality investing!.
1. IDXX Profitability Analysis
1.1 Basic Checks
- In the past year IDXX was profitable.
- IDXX had a positive operating cash flow in the past year.
- Each year in the past 5 years IDXX has been profitable.
- IDXX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- IDXX's Return On Assets of 30.34% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
- IDXX's Return On Equity of 65.81% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
- IDXX's Return On Invested Capital of 40.35% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IDXX is significantly above the industry average of 8.92%.
- The 3 year average ROIC (37.60%) for IDXX is below the current ROIC(40.35%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- The Profit Margin of IDXX (24.65%) is better than 95.11% of its industry peers.
- In the last couple of years the Profit Margin of IDXX has grown nicely.
- IDXX has a Operating Margin of 31.34%. This is amongst the best in the industry. IDXX outperforms 98.91% of its industry peers.
- IDXX's Operating Margin has improved in the last couple of years.
- Looking at the Gross Margin, with a value of 61.72%, IDXX is in the better half of the industry, outperforming 64.67% of the companies in the same industry.
- IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. IDXX Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
- The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
- Compared to 5 years ago, IDXX has less shares outstanding
- The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
- IDXX has an Altman-Z score of 21.37. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
- IDXX has a better Altman-Z score (21.37) than 96.20% of its industry peers.
- The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of IDXX (1.04) is better than 90.22% of its industry peers.
- A Debt/Equity ratio of 0.53 indicates that IDXX is somewhat dependend on debt financing.
- The Debt to Equity ratio of IDXX (0.53) is comparable to the rest of the industry.
- Although IDXX's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.37 |
ROIC/WACC4
WACC10.09%
2.3 Liquidity
- A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
- IDXX has a worse Current ratio (1.18) than 82.07% of its industry peers.
- IDXX has a Quick Ratio of 1.18. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.87, IDXX is doing worse than 82.07% of the companies in the same industry.
- IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. IDXX Growth Analysis
3.1 Past
- IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.18%, which is quite good.
- IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.26% yearly.
- Looking at the last year, IDXX shows a quite strong growth in Revenue. The Revenue has grown by 10.42% in the last year.
- IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.72% yearly.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- The Earnings Per Share is expected to grow by 13.75% on average over the next years. This is quite good.
- Based on estimates for the next years, IDXX will show a quite strong growth in Revenue. The Revenue will grow by 9.46% on average per year.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. IDXX Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 46.55, which means the current valuation is very expensive for IDXX.
- Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 69.57% of the companies listed in the same industry.
- IDXX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.29.
- A Price/Forward Earnings ratio of 41.06 indicates a quite expensive valuation of IDXX.
- 68.48% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 24.57. IDXX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.55 | ||
| Fwd PE | 41.06 |
4.2 Price Multiples
- 67.39% of the companies in the same industry are more expensive than IDXX, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 71.74% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.67 | ||
| EV/EBITDA | 34.39 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
- IDXX has an outstanding profitability rating, which may justify a higher PE ratio.
- IDXX's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.48
PEG (5Y)3.26
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. IDXX Dividend Analysis
5.1 Amount
- IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IDXX Fundamentals: All Metrics, Ratios and Statistics
608.41
-10.51 (-1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner Change11.43%
Ins Owners0.21%
Ins Owner Change2.2%
Market Cap48.58B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target768.59 (26.33%)
Short Float %2.2%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)-1.91%
PT rev (3m)-0.59%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.06%
EPS NY rev (1m)0.19%
EPS NY rev (3m)2.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.55 | ||
| Fwd PE | 41.06 | ||
| P/S | 11.66 | ||
| P/FCF | 51.67 | ||
| P/OCF | 44.65 | ||
| P/B | 31.12 | ||
| P/tB | 47.04 | ||
| EV/EBITDA | 34.39 |
EPS(TTM)13.07
EY2.15%
EPS(NY)14.82
Fwd EY2.44%
FCF(TTM)11.77
FCFY1.94%
OCF(TTM)13.63
OCFY2.24%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.48
PEG (5Y)3.26
Graham Number75.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.37 |
F-Score8
WACC10.09%
ROIC/WACC4
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.71%
EBIT Next 3Y14.82%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 46.55 and the Price/Book (PB) ratio is 31.12.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 13.36% in the next year.